Logo
x

Search

Subscribe Now

roche

Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)

Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)

  • October 21, 2024
Roche Highlights 2-Years Data from RAINBOWFISH Trial of Evrysdi for Treating Children with Spinal Muscular Atrophy (SMA) at WMS 2024

Roche Highlights 2-Years Data from RAINBOWFISH Trial of Evrysdi for Treating Children with Spinal Muscular Atrophy (SMA) at WMS 20...

  • October 14, 2024
Roche’s Reports the US FDA’s Approval of Itovebi as a Treatment for HR+ and HER2- breast cancer with a PIK3CA mutation

Roche’s Reports the US FDA’s Approval of Itovebi as a Treatment for HR+ and HER2- breast cancer with a PIK3CA mutation

  • October 11, 2024
Roche’s Ventana CLDN18 (43-14A) RxDx Assay Receives CE Mark Approval to Diagnose G/GEJ Cancer Patients with CLDN18 Protein Expression

Roche’s Ventana CLDN18 (43-14A) RxDx Assay Receives CE Mark Approval to Diagnose G/GEJ Cancer Patients with CLDN18 Protein Express...

  • October 10, 2024
Roche Reports Topline Data from P-III (REGENCY) Trial of Gazyva/Gazyvaro (Obinutuzumab) for Treating Lupus Nephritis

Roche Reports Topline Data from P-III (REGENCY) Trial of Gazyva/Gazyvaro (Obinutuzumab) for Treating Lupus Nephritis

  • September 26, 2024
Roche Reports Topline Data from P-III (CENTERSTONE) Study of Xofluza to Reduce the Transmission of Influenza Virus

Roche Reports Topline Data from P-III (CENTERSTONE) Study of Xofluza to Reduce the Transmission of Influenza Virus

  • September 19, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.